Presentation Type
Thesis
Department
Chemistry
Description
Photodynamic cancer therapy (PDT) is a type of treatment involving the use of light in conjunction with a photosensitive agent- a chemical or series of chemicals designed for activation when exposed to light. This research project investigated the synthesis and identification of the novel photosensitive agent, H2TPP-Pro-OH. To create the water-soluble porphyrin, (S)-(+)-prolinol was reacted with the tetra-carboxyl porphyrin, H2TPPC, to form the final H2TPP-Pro-OH product. This compound was then purified using syringe filtration and column chromatography, and subsequently characterized using infrared (IR), nuclear magnetic resonance (NMR), and Ultraviolet-visible (UV-vis) spectroscopies, as well as High Performance Liquid Chromatography (HPLC). Finally, the utility of the material as a PDT agent was determined by examining the cytotoxicity of the H2TPP-Pro-OH product using an MTT assay on MDA-MB-231 triple negative breast cancer (TNBC) cells comparing dark and light exposure.
Included in
Developing a New Water-Soluble Porphyrin as a Potential Photodynamic Cancer Therapy Agent
Photodynamic cancer therapy (PDT) is a type of treatment involving the use of light in conjunction with a photosensitive agent- a chemical or series of chemicals designed for activation when exposed to light. This research project investigated the synthesis and identification of the novel photosensitive agent, H2TPP-Pro-OH. To create the water-soluble porphyrin, (S)-(+)-prolinol was reacted with the tetra-carboxyl porphyrin, H2TPPC, to form the final H2TPP-Pro-OH product. This compound was then purified using syringe filtration and column chromatography, and subsequently characterized using infrared (IR), nuclear magnetic resonance (NMR), and Ultraviolet-visible (UV-vis) spectroscopies, as well as High Performance Liquid Chromatography (HPLC). Finally, the utility of the material as a PDT agent was determined by examining the cytotoxicity of the H2TPP-Pro-OH product using an MTT assay on MDA-MB-231 triple negative breast cancer (TNBC) cells comparing dark and light exposure.